The University of Pittsburgh was awarded a $499,999 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "NONTOXIC IMMUNOSUPPRESSION FOR VCA WITH VITAMIN D3 ANALOGUES". This 2-year federal grant, with a performance period from September 1, 2024 to August 31, 2026, supports the university's biomedical research efforts focused on developing innovative, non-toxic immunosuppressive treatments for vascularized composite allotransplantation (VCA) using vitamin D3 analogues. As a major academic research institution, the University of Pittsburgh has extensive capabilities in biomedical sciences and frequently partners with government agencies like the Department of Defense on federally funded projects addressing national priorities in military medicine and public health.
Generated 3/4/25, 5:02 AM